Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. The company has licensed the North American rights to Firdapse?, a proprietary form of amifampridine phosphate, or chemically known as 3,4-diaminopyridine phosphate, from BioMarin Pharmaceutical Inc. for the treatment of patients with Lambert-Eaton Myasthenic Syndrome, Congenital Myasthenic Syndromes and Myasthenia Gravis. In addition, the company has launched Firdapse? in the United States, selling through a field force in neurologic, central nervous system or rare disease products consisting of field personnel.

Evolving Systems is a provider of real-time digital engagement solutions and services. The company's digital engagement solutions portfolio includes: Acquisition and Activation, which consist of Smart Dealer, Dynamic SIM Allocation?, Tertio? Service Activation, and Number Inventory and Management; Customer Analytics and Value Management, which consist of The Profiling Engine, The Campaign Engine, Campaign Modules, Social Media Integration, and App Promotion; and Customer Retention and Loyalty, which consist of Loyalty Points and Programs, Coupon, Voucher and Badges Management, and Digital Engagement Engine.

Safehold is a holding company. Through its subsidiaries, the company operates its business through one segment by acquiring, managing and capitalizing ground leases. Ground leases generally represent the ownership of land underlying commercial real estate properties, which are leased on a long-term basis (base terms are 30 to 99 years, often with tenant renewal options) by the land owner to a tenant that owns and operates the building on top of the land, or what the company refer to as a Safehold?.

Tela Bio is a commercial stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company offers a portfolio of advanced reinforced tissue matrices that improve clinical outcomes and reduce overall costs of care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery. The company's products are an innovative solution that integrate multiple layers of minimally-processed biologic material with interwoven polymers in a unique embroidered pattern, which the company refers to as a reinforced tissue matrix. The company serves customers in the United States.